Mesoblast Limited (MESO)
NASDAQ: MESO · Real-Time Price · USD
20.40
+0.34 (1.69%)
At close: Feb 4, 2025, 4:00 PM
19.60
-0.80 (-3.92%)
After-hours: Feb 4, 2025, 6:35 PM EST
Mesoblast Revenue
In the fiscal year ending June 30, 2024, Mesoblast had annual revenue of $5.90M, down -21.32%. Mesoblast had revenue of $1.26M in the quarter ending June 30, 2024, a decrease of -41.23%.
Revenue (ttm)
$5.90M
Revenue Growth
-21.32%
P/S Ratio
n/a
Revenue / Employee
$80,849
Employees
73
Market Cap
2.40B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2024 | 5.90M | -1.60M | -21.32% |
| Jun 30, 2023 | 7.50M | -2.71M | -26.54% |
| Jun 30, 2022 | 10.21M | 2.78M | 37.36% |
| Jun 30, 2021 | 7.43M | -24.72M | -76.88% |
| Jun 30, 2020 | 32.16M | 15.43M | 92.30% |
| Jun 30, 2019 | Pro | Pro | Pro |
| Jun 30, 2018 | Pro | Pro | Pro |
| Jun 30, 2017 | Pro | Pro | Pro |
| Jun 30, 2016 | Pro | Pro | Pro |
| Jun 30, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 63.17B |
| AbbVie | 56.33B |
| Novartis AG | 51.72B |
| AstraZeneca | 51.21B |
| Thermo Fisher Scientific | 42.88B |
| Abbott Laboratories | 41.95B |
MESO News
- 5 days ago - Ryoncil® Commercial Launch Update and Product Pipeline - GlobeNewsWire
- 5 days ago - Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2024 - GlobeNewsWire
- 25 days ago - Top 2 Health Care Stocks That Are Ticking Portfolio Bombs - Benzinga
- 6 weeks ago - Mesoblast's Cell Therapy Treatment For Graft Versus Host Disease Gets FDA Approval, Stock Surges - Benzinga
- 6 weeks ago - Mesoblast's RYONCIL® is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy - GlobeNewsWire
- 6 weeks ago - US FDA approves Mesoblast's cell therapy for graft-versus-host disease - Reuters
- 6 weeks ago - Mesoblast to be Added to Nasdaq Biotechnology Index - GlobeNewsWire
- 7 weeks ago - RFK Jr. could prove a surprise boon for stem-cell stocks with pivotal year ahead - Market Watch